Low Systemic Inflammation Response Index Predicts Good Prognosis in Locally Advanced Pancreatic Carcinoma Patients Treated with Concurrent Chemoradiotherapy
Background. We investigated the prognostic significance of pretreatment systemic inflammation response index (SIRI) in locally advanced pancreatic carcinoma (LAPC) patients treated with concurrent chemoradiotherapy (CRT). Methods. Present retrospective cohort analysis investigated consecutive 154 LA...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2020-01-01
|
| Series: | Gastroenterology Research and Practice |
| Online Access: | http://dx.doi.org/10.1155/2020/5701949 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832568598439133184 |
|---|---|
| author | Erkan Topkan Huseyin Mertsoylu Ahmet Kucuk Ali Ayberk Besen Ahmet Sezer Duygu Sezen Yasemin Bolukbasi Ugur Selek Berrin Pehlivan |
| author_facet | Erkan Topkan Huseyin Mertsoylu Ahmet Kucuk Ali Ayberk Besen Ahmet Sezer Duygu Sezen Yasemin Bolukbasi Ugur Selek Berrin Pehlivan |
| author_sort | Erkan Topkan |
| collection | DOAJ |
| description | Background. We investigated the prognostic significance of pretreatment systemic inflammation response index (SIRI) in locally advanced pancreatic carcinoma (LAPC) patients treated with concurrent chemoradiotherapy (CRT). Methods. Present retrospective cohort analysis investigated consecutive 154 LAPC patients who received radical CRT. The SIRI was defined as: SIRI=neutrophil×monocyte/lymphocyte counts. Ideal SIRI cutoff(s) influencing overall survival (OS) and progression-free survival (PFS) results were sought by using receiver operating characteristic (ROC) curve analysis. The primary endpoint was the interaction between the SIRI and OS results. Results. The median follow-up, PFS, and OS durations were 14.3 (range: 2.9-74.6), 7.9 [%95 confidence interval (CI): 5.7-10.1), and 14.7 months (%95 CI: 11.4-18.0) for the entire cohort, respectively. ROC curve analyses determined the ideal SIRI cutoff that exhibiting a significant link with OS and PFS outcomes at the rounded 1.6 point (AUC: 74.3%; sensitivity: 73.8%; specificity: 70.1%).The SIRI <1.6 patients (N=58) had significantly superior median PFS (13.8 versus 6.7 months; P<0.001) and OS (28.6 versus 12.6 months; P<0.001) lengths than SIRI ≥1.6 patients (N=96), respectively. Although the N0 (versus N1; P<0.05) and CA 19-9 ≤90 U/mL (versus >90 U/mL) appeared as the other significant associates of better OS and PFS in univariate analyses, yet the results of multivariate analyses confirmed the SIRI <1.6 as the independent indicator of superior OS and PFS (P<0.001 for each). Conclusion. Pretreatment SIRI is a novel independent prognosticator that may further enhance the conventional tumor-node-metastases staging system in a more precise prediction of the OS and PFS outcomes of LAPC patients after radical CRT. |
| format | Article |
| id | doaj-art-c7d2c5f78af04999aaeaa487e023879a |
| institution | Kabale University |
| issn | 1687-6121 1687-630X |
| language | English |
| publishDate | 2020-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Gastroenterology Research and Practice |
| spelling | doaj-art-c7d2c5f78af04999aaeaa487e023879a2025-02-03T00:58:48ZengWileyGastroenterology Research and Practice1687-61211687-630X2020-01-01202010.1155/2020/57019495701949Low Systemic Inflammation Response Index Predicts Good Prognosis in Locally Advanced Pancreatic Carcinoma Patients Treated with Concurrent ChemoradiotherapyErkan Topkan0Huseyin Mertsoylu1Ahmet Kucuk2Ali Ayberk Besen3Ahmet Sezer4Duygu Sezen5Yasemin Bolukbasi6Ugur Selek7Berrin Pehlivan8Department of Radiation Oncology, Baskent University Medical Faculty, Adana, TurkeyDepartment of Medical Oncology, Baskent University Medical Faculty, Adana, TurkeyMersin City Education and Research Hospital, Radiation Oncology Clinics, Mersin, TurkeyDepartment of Medical Oncology, Baskent University Medical Faculty, Adana, TurkeyDepartment of Medical Oncology, Baskent University Medical Faculty, Adana, TurkeyDepartment of Radiation Oncology, Koc University School of Medicine, Istanbul, TurkeyDepartment of Radiation Oncology, Koc University School of Medicine, Istanbul, TurkeyDepartment of Radiation Oncology, Koc University School of Medicine, Istanbul, TurkeyDepartment of Radiation Oncology, Bahcesehir University, Istanbul/, TurkeyBackground. We investigated the prognostic significance of pretreatment systemic inflammation response index (SIRI) in locally advanced pancreatic carcinoma (LAPC) patients treated with concurrent chemoradiotherapy (CRT). Methods. Present retrospective cohort analysis investigated consecutive 154 LAPC patients who received radical CRT. The SIRI was defined as: SIRI=neutrophil×monocyte/lymphocyte counts. Ideal SIRI cutoff(s) influencing overall survival (OS) and progression-free survival (PFS) results were sought by using receiver operating characteristic (ROC) curve analysis. The primary endpoint was the interaction between the SIRI and OS results. Results. The median follow-up, PFS, and OS durations were 14.3 (range: 2.9-74.6), 7.9 [%95 confidence interval (CI): 5.7-10.1), and 14.7 months (%95 CI: 11.4-18.0) for the entire cohort, respectively. ROC curve analyses determined the ideal SIRI cutoff that exhibiting a significant link with OS and PFS outcomes at the rounded 1.6 point (AUC: 74.3%; sensitivity: 73.8%; specificity: 70.1%).The SIRI <1.6 patients (N=58) had significantly superior median PFS (13.8 versus 6.7 months; P<0.001) and OS (28.6 versus 12.6 months; P<0.001) lengths than SIRI ≥1.6 patients (N=96), respectively. Although the N0 (versus N1; P<0.05) and CA 19-9 ≤90 U/mL (versus >90 U/mL) appeared as the other significant associates of better OS and PFS in univariate analyses, yet the results of multivariate analyses confirmed the SIRI <1.6 as the independent indicator of superior OS and PFS (P<0.001 for each). Conclusion. Pretreatment SIRI is a novel independent prognosticator that may further enhance the conventional tumor-node-metastases staging system in a more precise prediction of the OS and PFS outcomes of LAPC patients after radical CRT.http://dx.doi.org/10.1155/2020/5701949 |
| spellingShingle | Erkan Topkan Huseyin Mertsoylu Ahmet Kucuk Ali Ayberk Besen Ahmet Sezer Duygu Sezen Yasemin Bolukbasi Ugur Selek Berrin Pehlivan Low Systemic Inflammation Response Index Predicts Good Prognosis in Locally Advanced Pancreatic Carcinoma Patients Treated with Concurrent Chemoradiotherapy Gastroenterology Research and Practice |
| title | Low Systemic Inflammation Response Index Predicts Good Prognosis in Locally Advanced Pancreatic Carcinoma Patients Treated with Concurrent Chemoradiotherapy |
| title_full | Low Systemic Inflammation Response Index Predicts Good Prognosis in Locally Advanced Pancreatic Carcinoma Patients Treated with Concurrent Chemoradiotherapy |
| title_fullStr | Low Systemic Inflammation Response Index Predicts Good Prognosis in Locally Advanced Pancreatic Carcinoma Patients Treated with Concurrent Chemoradiotherapy |
| title_full_unstemmed | Low Systemic Inflammation Response Index Predicts Good Prognosis in Locally Advanced Pancreatic Carcinoma Patients Treated with Concurrent Chemoradiotherapy |
| title_short | Low Systemic Inflammation Response Index Predicts Good Prognosis in Locally Advanced Pancreatic Carcinoma Patients Treated with Concurrent Chemoradiotherapy |
| title_sort | low systemic inflammation response index predicts good prognosis in locally advanced pancreatic carcinoma patients treated with concurrent chemoradiotherapy |
| url | http://dx.doi.org/10.1155/2020/5701949 |
| work_keys_str_mv | AT erkantopkan lowsystemicinflammationresponseindexpredictsgoodprognosisinlocallyadvancedpancreaticcarcinomapatientstreatedwithconcurrentchemoradiotherapy AT huseyinmertsoylu lowsystemicinflammationresponseindexpredictsgoodprognosisinlocallyadvancedpancreaticcarcinomapatientstreatedwithconcurrentchemoradiotherapy AT ahmetkucuk lowsystemicinflammationresponseindexpredictsgoodprognosisinlocallyadvancedpancreaticcarcinomapatientstreatedwithconcurrentchemoradiotherapy AT aliayberkbesen lowsystemicinflammationresponseindexpredictsgoodprognosisinlocallyadvancedpancreaticcarcinomapatientstreatedwithconcurrentchemoradiotherapy AT ahmetsezer lowsystemicinflammationresponseindexpredictsgoodprognosisinlocallyadvancedpancreaticcarcinomapatientstreatedwithconcurrentchemoradiotherapy AT duygusezen lowsystemicinflammationresponseindexpredictsgoodprognosisinlocallyadvancedpancreaticcarcinomapatientstreatedwithconcurrentchemoradiotherapy AT yaseminbolukbasi lowsystemicinflammationresponseindexpredictsgoodprognosisinlocallyadvancedpancreaticcarcinomapatientstreatedwithconcurrentchemoradiotherapy AT ugurselek lowsystemicinflammationresponseindexpredictsgoodprognosisinlocallyadvancedpancreaticcarcinomapatientstreatedwithconcurrentchemoradiotherapy AT berrinpehlivan lowsystemicinflammationresponseindexpredictsgoodprognosisinlocallyadvancedpancreaticcarcinomapatientstreatedwithconcurrentchemoradiotherapy |